264 results on '"Li, Abby A."'
Search Results
2. Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects
3. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments
4. Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use
5. Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review
6. Practical considerations for developmental thyroid toxicity assessments: What's working, what's not, and how can we do better?
7. List of Contributors
8. Target sites: nervous system
9. Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer’s Disease
10. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2)
11. Workgroup Report: Incorporating In Vitro Alternative Methods for Developmental Neurotoxicity into International Hazard and Risk Assessment Strategies
12. Methods to Identify and Characterize Developmental Neurotoxicity for Human Health Risk Assessment. III: Pharmacokinetic and Pharmacodynamic Considerations
13. Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
14. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005–2017)
15. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
16. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab
17. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)
18. Subchronic, reproductive, and maternal toxicity studies with tertiary butyl acetate (TBAC)
19. Predictors of readmission to a psychiatry inpatient unit
20. Glyphosate and neurological outcomes: A systematic literature review of animal studies
21. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study
22. Strategies and tools for preventing neurotoxicity: To test, to predict and how to do it
23. Integration of epidemiology and animal neurotoxicity data for risk assessment
24. Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects
25. Reply: Endotoxin, a Possible Agent in the Causation of Parkinson's Disease
26. Evaluation of Epidemiologic and Animal Data Associating Pesticides With Parkinson's Disease
27. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
28. Oral gavage subchronic neurotoxicity and inhalation subchronic immunotoxicity studies of ethylbenzene in the rat
29. Diagnostic criteria for apathy in neurocognitive disorders
30. A descriptive study of older medical cannabis users in medical cannabis clinics
31. Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer’s Disease Relieve Caregiver Burden?
32. Building a scientific framework for studying hormonal effects on behavior and on the development of the sexually dimorphic nervous system
33. Chapter 58 - Target sites: nervous system
34. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial
35. A review of cost–effectiveness of palivizumab for respiratory syncytial virus
36. Target Sites
37. List of Contributors
38. Genotoxicity as a toxicologically relevant endpoint to inform risk assessment: A case study with ethylene oxide
39. This is your teen brain on drugs: In search of biological factors unique to dependence toxicity in adolescence
40. What risk factors for sudden infant death syndrome are preterm and term medically complex infants exposed to at home?
41. Behavioral test methods workshop
42. Regulatory developmental neurotoxicology testing: data evaluation for risk assessment purposes
43. A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab.
44. What risk factors for sudden infant death syndrome are preterm and term medically complex infants exposed to at home?
45. Neurobehavioral Assessment: A Survey of Use and Value in Safety Assessment Studies
46. An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS)
47. 73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)
48. 72 Use of Palivizumab in Canada; Data from the CARESS registry 2005–2017
49. Reevaluation of Historical Exposures to Ethylene Oxide Among U.S. Sterilization Workers in the National Institute of Occupational Safety and Health (NIOSH) Study Cohort
50. Rates of Screening for Breast, Colorectal, and Cervical Cancers in Older People With Cognitive Impairment or Dementia: A Meta-Analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.